Efficacy and Safety Study of Magnesium Iron Hydroxycarbonate for the Reduction of High Blood Phosphate in Hemodialysis Patients

Inclusion Criteria: * Male or female subjects on active haemodialysis, aged 18 years or over. * Written informed consent given. * On a stable haemodialysis regimen (three times per week) for at least 3 months and be unlikely to change their dialysis prescription during the study period. * On a stable dose of a phosphate binder for at least 1 month prior to screening. * Willing to abstain from taking any phosphate binder or oral magnesium, aluminum or iron-containing products and preparations, other than the study medication. * Willing to avoid any intentional changes in diet such as fasting, dieting or overeating. * Willing to maintain their usual type and dose of Vitamin D supplementation. Exclusion Criteria: * Participation in any other clinical trial using an investigational product or device within the previous 4 months. * A significant history of alcohol, drug or solvent abuse in the opinion of the investigator. * Any disease or condition, physical or psychological, which in the opinion of the investigator would compromise the safety of the subject or increase the likelihood of the subject being withdrawn. * Clinically significant laboratory findings (for this subject population) in the opinion of the investigator. * Any malignancy requiring treatment within 5 years of screening with the exception of basal cell carcinoma and Bowen's disease. * A history of a motility disorder of the intestines, including, but not limited to, gastroparesis, ileus, pseudo-obstruction, megacolon, or mechanical obstruction. * A significant illness in the 4 weeks before screening. * Taking medication prescribed for seizures. * A history of haemochromatosis. * A history of high serum ferritin concentration of ≥ 1000ng/ml (excluding transient, treatment-induced ferritin elevation). * A history of dysphagia or swallowing disorders that might limit the subject's ability to swallow study medication in the opinion of the investigator. * Female subjects who are lactating or pregnant. Women of childbearing potential (pre-menopausal and not surgically sterilized) unless they are using a reliable contraceptive method, that is, barrier methods, hormones or intrauterine device. * Current haemoglobin concentration of \< 10.00 g/dL. * Allergy to the IMP or its constituents.